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Abstract
Background: The therapy for cow's milk proteins allergy (CMPA) consists in eliminating cow's
milk proteins (CMP) from the child's diet. Ass's milk (AM) has been recently considered as
substitute of CMP. This prospective study investigated tolerance and nutritional adequacy of AM in
children with CMPA from Southern Italy.
Methods: Thirty children (aged 6 months to 11 years) with suspected CMPA were enrolled. They
underwent skin prick tests and bouble-blind, placebo controlled food challenge to CMP. After
confirming the diagnosis of CMPA, patients received fresh AM in a open challenge. Specific serum
CMP and AM IgE, and biochemical parameters in blood were also assessed. Auxological evaluations
were performed in all subjects at entry (T0) and after 4–6 months (T1) of AM intake.
Results: Twenty-five children resulted elegible for the study, and 24 out of 25 subjects (96%)
tolerated AM at the food challenge. Auxological data resulted improved by the end of the study in
all patients, while blood biochemical parameters did not vary during the follow-up.
Conclusion: Our data confirm the high rate of AM tolerability in children with moderate
symptoms of CMPA. Moreover, we found that AM seems to have nutritional adequacy in subjects
with a varied diet.
Introduction
Cow's milk protein allergy (CMPA) is a common disease
occurring in childhood and its prevalence approximates
3% during the first 3 years of life [1]. Clinical manifesta-
tions of CMPA are atopic dermatitis (AD), urticaria/
angioedema, gastrointestinal symtoms, and less fre-
quently, respiratory disorders, such as wheezing and
asthma. The therapy for CMPA consists in eliminating
cow's milk proteins (CMP) from the child's diet. Exten-
sively hydrolyzed formulas (eHF) are currently the most
used substitutes of CMP. They have a good nutritional
value, but are not tolerated by all patients with CMPA, are
quite expensive and present poor palatability. Also
amino-acid formulas have an unpleasant taste, and
should be considered in severe clinical manifestations of
food allergy or when eHF are not effective [2]. Soy pro-
tein-based formulas have a moderate palatability and pro-
vide appropriate nutrition. However there are not
reccommended for the tratment of young children with
CMPA because of the potential to evoke allergic reactions
[3]. For these reasons, other mammalian milks have been
considered to replace cow's milk (CM), including ass's
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to that of human milk [4,5]. Furthermore, AM has an
acceptable taste. There are in literature few clinical Italian
studies concerning the allergenicity and tolerability of
AM, and their results are not conclusive [6-8]. Recently,
Monti et al. have documented that the tolerability of AM
was 82.6% in their selected cohort of children with
CMPA, without other alternative to the use of common
CMP substitutes [6]. Other Authors have emphasized the
risk of potential cross-reactivity between CMP and AM
proteins, suggesting that more in vivo and in vitro studies
are required to optimize dietary needs for infants with
CMPA [9]. Furthermore, some authors have found an
impaired growth in infants affected by CMPA, who
received different type of CMP substitutes [10]. We aimed
to investigate the AM tolerability and nutitional adequacy
in children with CMPA from Apulia, a Southern Italy
region where AM is readily available and frequently used
also in healthy children.
Methods
Between January and July 2008 we recruited 30 consecu-
tive children who attended our University Department of
Pediatric Allergy and Immunology. Inclusion criteria
were: i) suspected clinical history of CMPA; ii) absence of
concomitant chronic diseases; iii) antihistamine therapy
and/or systemic corticosterois not administred in the 4
week preceeding the study. The local Ethics Committee
approved the study protocol. Informed consent to parteci-
pate to the study was obtained from the participants or
legal guardians. Patients underwent a full history and
physical examination at entry. The diagnosis of CMPA was
made on the basis of a CMP elimination diet (for 4
weeks), followed by bouble-blind, placebo controlled
food challenge (DBPCFC). The DBPCFCs were performed
at the clinic, with full facilities for resuscitation available.
Fresh CM was administred at increasing doses of 0.1, 0.3,
1.0, 3.0, 10.0, 30.0, and 100 ml, using Neocate® (Nutricia,
Liverpool, UK) as placebo. Pear juice was mixed to both
CM and placebo in equal parts to mask the taste. The time
interval between each dose was 20 min [11]. After com-
pleting the DBPCFC, children were kept under observa-
tion for at least 6 h and then discharged. Before food
challenge, skin prick tests (SPT) were also performed
using fresh CM, AM, pear juice and other common food-
and aero-allergens, according to a protocol described else-
where (positive if wheal diameter > 3 mm) [12]. Serum
levels of specific IgE (alpha-lactalbumin, beta-lactoglobu-
lin, casein, AM) were determined by the automated Phar-
macia CAP System FEIA (Pharmacia Diagnostics AB,
Uppsala, Sweden), with a cut-off point for positivity set at
0.35 KU/l.
After confirming the diagnosis of CMPA by DBPCFC,
patients received fresh AM (ass-farming of Alberobello,
Bari, Italy) in a open challenge, as described for CM. Fresh
AM was analyzed for sterility criteria by the Experimental
Zooprophylactic Institute of Putignano, Bari, Italy. In case
of clinical tolerance, AM was included into the child's diet,
which was appropriately balanced depending on age
requirements.
The study design included follow-up in the form of clini-
cal check-up and auxological evaluation at entry (T0), and
after 4–6 months (T1) of AM consumption.
Standing height (H) was evaluated with a wall-mounted
Harpenden Stadiometer. With patients in underwear,
weight (W) was measured with an electronic scale with
digital readings accurate to 0.1 kg. Body mass index (BMI)
was calculated dividing W in kilograms by the square of H
in meters, and it was expressed as centiles according to the
Italian growth charts [13].
Blood levels of biochemical and metabolic parameters
(iron, calcium, proteins, cholesterol, triglycerides, glycae-
mia, folic acid, etc.) from all subjects, were assessed at
each observational time period. Also hidden faecal blood
was sought at the beginning and at the end of the study.
Statistical analysis
Statistical analyses were performed using SPSS® for Win-
dows software (SPSS Inc., version 15.0, Chicago, IL). Data
were expressed as the mean ± SD. Mann-Whitney tests
were used to compare groups, and correlations between
variables were performed using the Sperman rank correla-
tion test. Paired-samples t test was used to compare data
before and after AM intake for the group of CMPA
patients. Significance was defined as p < 0.05.
Results
All enrolled children fulfilled the inclusion criteria. Symp-
toms at first observation were cutaneous (atopic dermati-
tis, 24/20; urticaria/angioedema, 14/30), gastrointestinal
(12/30), and/or respiratory (8/30). Patient's clinical data
are summarized in Table 1. Twenty-seven children (90%)
were affected by an IgE-mediated form of CMPA, while
only two subjects (7%), who presented gastrointestinal
manifestations, had a non IgE-mediated CMPA, with neg-
ative SPT and CMP-specific IgE. All patients were SPT-neg-
ative for pear juice.
The CMPA was confirmed with DBPCFC in 28 children.
The parents of one out of two children with SPT positive
for AM and the concomitant presence of serum specific
IgE for AM refused to give their consent to the ass's milk
challenge. In two other cases parents of childs with severe
reactions to CM challege did not consent to continue the
study. The AM was tolerated by 24 out of 25 children who
were tested with the food challenge (22 with IgE-mediatedPage 2 of 4
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with CMPA and positive AM specific IgE and SPT for AM
had a systemic reaction at the food challenge with cutane-
ous lesions, cought and vomiting.
The auxological evaluations at enrolement (T0) and at the
end of the study (T1) are shown in Table 2. All children
had an improvement of their W and H at T1. Moreover, at
entry all children presented a BMI corresponding to the
normalweight (50° centile), which was kept unchanged
by the end of the study.
Any relevant variation of blood biochemical and meta-
bolic parameters was observed (data not shown), and also
the faecal tests resulted negative.
Discussion
In this study we report an experience on clinical tolerabil-
ity of AM, which was high at the food challenge (24/25,
96%), made in an Italian Region, Apulia, where AM is
readily available and frequently used because of the pres-
ence of several ass's farming. AM was tolerated by our
patients either with the IgE- and the non-IgE-mediated
CMPA. All enrolled subjects found it acceptable due to its
palatability, and did not interrupted the study. AM has
been considered an alternative to CM considering that its
protein composition is similar to human milk [14]. How-
ever, it is a low-calory food and thus in our study we
enrolled children older than 6 months who did not have
an exclusive milk diet. It is noteworthy to highlight the
fact that patients with severe reaction to CM refused to
continue this study, thus our results are referred to sub-
jects with a mild to moderate form of CMPA. Only one
recruited patient had a systemic food reaction during the
AM challenge. He was the only tested child who had SPT
positive for AM and high serum levels of AM specific IgE,
suggesting the predictive positive value of these tests also
for AM allergy.
Other Italian authors have documented the efficacy of this
food in treating children with CMPA. Vita et al. showed
that the rate of tolerability of AM in patients with AD and
CMPA was 88%, and that AM improved child's eczema
[7]. Similarly, Monti et al. assessed the tolerance of AM
(82.6%) in a selected population of children with CMPA,
for whom it was not possible to use any other cow's milk
substitute [6]. However, it must be taken into account the
potential cross-reactivity of AM proteins with CMP, also
suggested by the above mentioned studies that reported
some severe reactions to AM in their study cohorts [6-9].
Furthermore, our data show an adequate increase in
weight and length/stature in all recruited children. Their
BMI centiles measured after 4–6 months of AM adminis-
tration were stable compared to those at the beginning of
the study. Similar observations were reported by Monti in
the early months of AM intake [6]. These Authors con-
cluded that the effect on growth of AM is related to its abil-
ity to fill some nutritional gaps present in the diet of the
subjects treated. Other authors have found an impaired
growth in infants affected by CMPA, who received differ-
ent type of CMP substitutes [10]. We suggest that a longer
follow-up study is needed in order to reach reliable
results. We also verified that patients' biochemical and
metabolic parameters in the blood did not vary during the
study period. Taken toghether these results suggest that
Table 1: Characteristics of the patients enrolled in the study
Patient's Characteristics
Male/Female ratio 1:1
Age (y), median (range) 4.5 (6.0 mo-10 y)
Total serum IgE at baseline (IU/mL) 335,93
Positive Skin Prick Tests to: (n)
Cow's milk 27
Ass's milk 2
Wheat 2
Hen's egg 7
Soy 4
Pollens 5
Dust mite 7
Molds 2
Pets with fur 4
Positive specific IgE to: (n)
alpha-lactalbumin 21
beta-lactoglobulin 17
casein 9
Ass's milk 2
Table 2: Auxological parameters of the study population by sex 
and age at enrolement (T0) and at the end of the study (T1)
W (Kg) mean ± SD H (cm) mean ± SD BMI mean ± SD
(centiles)
All children
T0 17,3 ± 9,6 T0 100,3 ± 14,9 T0 16,1 ± 1,5 (50°)
T1 19,4 ± 11,6 T1 105,4 ± 23,2 T1 16,0 ± 2,1 (50°)
p = 0.02 p < 0.001 p = ns
Boys
T0 16,9 ± 6,7 T0 102,2 ± 23,7 T0 15,8 ± 1,1 (50°)
T1 18,3 ± 7,2 T1 106,3 ± 20,8 T1 15,6 ± 0,8 (50°)
p < 0.01 p = 0.03 p = ns
Girls
T0 17,9 ± 13,3 T0 98,1 ± 29,0 T0 16,5 ± 2,0 (50°)
T1 20,6 ± 16,4 T1 104,2 ± 28,2 T1 16,6 ± 3,0 (50°)
p = ns p < 0.01 p = ns
*p significance for Paired T-test
ns = not significantPage 3 of 4
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AM might be considered nutritionally adequate in chil-
dren with a varied diet.
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